

Enabling a Southeast Asia Without TB

Johnson & Johnson is collaborating with governments and organizations across Southeast Asia to comprehensively address the challenges of tuberculosis (TB) and antimicrobial resistance (AMR).



THE CHALLENGE

TB remains a critical health challenge in many countries in Southeast Asia, including Indonesia, the Philippines, Malaysia, Myanmar, Thailand and Vietnam. The World Health Organization (WHO) estimated that in 2021, there were about 71,500 new cases of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) in these 6 countries.¹ However, only about 30% (21,219) of these MDR/RR-TB cases were diagnosed and 16,160 were enrolled in treatment in 2021.¹

To end TB across Southeast Asia, it is essential to accelerate the development and delivery of new innovations from the lab to the last mile of health to help reach more patients.

ACTION TO END TB

Johnson & Johnson is working closely with countries in Southeast Asia to tackle TB in support of national TB goals and commitments and the UN Sustainable Development Goal target of ending TB by 2030. Our efforts are aimed at catalyzing innovation and furthering collaboration from the lab to the last mile of health delivery.

Our treatment, the first medicine with a novel mechanism of action against MDR-TB in more than 40 years, was introduced in the region in 2014. Johnson & Johnson Philippines received the first regulatory approval for the medicine (2014), followed by Thailand (2017), Indonesia (2018) and Malaysia (2020).

From 2015-2019, Johnson & Johnson provided our MDR-TB medicine through a four-year donation program to support patient access in low- and middle-income countries, including Indonesia, Philippines, Myanmar, Thailand and Vietnam. Today, our medicine is available to these and more than 135 low- and middle-income countries through the Stop TB Partnership's Global Drug Facility (GDF) and via local procurement.

Johnson & Johnson is also leading a concerted regional effort across Indonesia, the Philippines, Thailand and Vietnam to engage youth to take charge of their countries' TB trajectory by actively managing their own health and advocating for those around them.

These efforts are part of a comprehensive 10-year TB initiative launched by Johnson & Johnson in September 2018 focused on enabling access to treatment regimens, finding the "missing millions" and accelerating the development of next-generation TB treatments.

GLOBAL PROGRAM AT A GLANCE



First novel medicine for TB in more than 40 years; approved in 72 countries



600K+ courses of treatment delivered for MDR-TB patients in 158 countries, including the 30 highest-burden countries



Donating 105K courses of treatment to eligible countries through a four-year donation program from 2015-2019 with USAID and JSC Pharmstandard, implemented through the Stop TB Partnership's Global Drug Facility

COLLABORATING AT EVERY LEVEL

Johnson & Johnson is taking a holistic approach to ending TB in the Southeast Asia region by supporting efforts to find the “missing millions” of cases of TB, training healthcare professionals to better manage TB and MDR-TB, and collaborating to accelerate affordable access to treatment regimens.



ACCESS

Provided our MDR-TB treatment free-of-charge to patients in eligible LMICs, including countries in Southeast Asia, through a four-year donation program (2015- 2019); since 2019, have provided access via the GDF and local procurement.



APPROPRIATE USE

Partnering with national TB programs, researchers, health authorities and NGOs across the region to promote appropriate use of our MDR-TB medicine through monitoring and local technical guidelines.

Supporting capacity building in clinical and programmatic DR-TB management for healthcare providers (HCPs) and other TB stakeholders across all countries in the region.




COMMUNITY EMPOWERMENT

Launched the ‘United Against TB’ campaign in 2022 – a regional effort to raise awareness about TB across Indonesia, Vietnam, Thailand and the Philippines to ultimately help positively impact notification rates and treatment success. This includes ‘TB Warriors,’ a multi-faceted game across online and social media platforms that provides youth with resources and information on TB in a fun and engaging way and aims to enhance health seeking behavior, linking communities to TB care.

COLLABORATIONS

- Indonesia:** Initiated a TB Industry Coalition with the Stop TB Partnership Indonesia, National Tuberculosis Program and CSOs to pursue presidential decree for DR-TB care; have supported Indonesia’s ‘Toss TB’ public awareness campaign for several years; collaborating in national TB elimination efforts coordinated by the TB Control Partnership Forum.
- Vietnam:** Ongoing collaboration with the National TB Program of Vietnam to strengthen the capacity of health workers in 63 provinces through medical education; building TB awareness at universities and provincial lung hospitals through the TB Warrior game; partnered with famous Vietnamese musician to raise awareness through the song “Dam Lao.”
- Philippines:** Strengthening the capacity of health workers in the country through an ongoing partnership with the UP Manila College of Public Health for the implementation of TB Academy and with the Philippine Business for Social Progress; continued patient finding initiatives both in the workplace and among youth and children, including through Project TBY in Barangays, to improve health seeking behavior.
- Myanmar:** Partnered with Greenshoot Myanmar to build capacity of HCPs in Yangon & Mandalay.



ABOUT J&J GLOBAL PUBLIC HEALTH

Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world’s most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformational products.

Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier, more equitable future.